<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   TRK fusion-positive cancers and TRK inhibitor therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       TRK fusion-positive cancers and TRK inhibitor therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        TRK fusion-positive cancers and TRK inhibitor therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alexander Drilon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2267406660">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tropomyosin receptor kinase (TRK) family of transmembrane receptor proteins (TRKA, TRKB, and TRKC) is encoded by the neurotrophic tyrosine receptor kinase (
         <em>
          NTRK
         </em>
         ) genes (
         <em>
          NTRK1
         </em>
         ,
         <em>
          NTRK2
         </em>
         , and
         <em>
          NTRK3
         </em>
         , respectively). All three TRK proteins can become targets of structural rearrangement caused by an
         <em>
          NTRK
         </em>
         gene fusion that results in a chimeric TRK fusion protein that drives uninterrupted downstream signaling, and as a result, these fusions have emerged as important targets for cancer therapy. Selective inhibitors of these fusion proteins have been shown to have robust and durable activity in TRK fusion-positive solid tumors, and two of these agents are now approved in the United States and elsewhere for treatment of TRK fusion-positive refractory solid tumors, regardless of the site of disease origin. As such, these represent "tissue-agnostic" drug approvals.
        </p>
        <p>
         This topic will review the prevalence, diagnosis, and management of TRK fusion-positive cancers.
        </p>
        <p class="headingAnchor" id="H2866469034">
         <span class="h1">
          MOLECULAR ALTERATIONS OF NTRK GENES IN VARIOUS TUMOR TYPES
         </span>
        </p>
        <p class="headingAnchor" id="H1440179546">
         <span class="h2">
          Basic biology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The TRK receptor family comprises three transmembrane proteins, TRKA, TRKB, and TRKC, which are encoded, respectively, by the neurotrophic tyrosine receptor kinase (
         <em>
          NTRK
         </em>
         ) 1 (which maps to chromosome 1q21-q22
         <em>
          )
         </em>
         ,
         <em>
          NTRK2
         </em>
         (which maps to chromosome 9q22.1), and
         <em>
          NTRK3
         </em>
         (which maps to chromosome 15q25) genes [
         <a href="#rid1">
          1
         </a>
         ]. These receptors are expressed in neuronal tissue and play a central role in nervous system development during embryogenesis [
         <a href="#rid2">
          2
         </a>
         ]. Following birth, the TRKs are primarily expressed by neuronal tissue and are involved in pain sensing, memory, weight homeostasis, and proprioception [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Fusions involving one of the
         <em>
          NTRK
         </em>
         genes were among the first gene translocations described in cancer [
         <a href="#rid4">
          4
         </a>
         ]. These structural rearrangements result in a TRK fusion oncoprotein that leads to overexpression of the kinase domain or constitutive activity of the kinase function, both of which drive uninterrupted downstream signaling messages and oncogenic transformation and tumor growth [
         <a href="#rid5">
          5-7
         </a>
         ]. Gene fusions represent the main molecular alterations in
         <em>
          NTRK
         </em>
         genes with known oncogenic and transforming potential [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Although dozens of unique
         <em>
          NTRK
         </em>
         fusions have been identified, they generally have shared features, including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An upstream fusion partner in the 5' (upstream) position that is typically expressed in the tissue type in which it is found
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inclusion of the full-length TRK kinase domain in the 3' (downstream) position
        </p>
        <p>
        </p>
        <p>
         Although fusions may occur in any of the three
         <em>
          NTRK
         </em>
         genes, most of those identified to date involve either
         <em>
          NTRK3
         </em>
         or
         <em>
          NTRK1
         </em>
         [
         <a href="#rid5">
          5,8,9
         </a>
         ].
        </p>
        <p>
         This topic will preferentially use the term "TRK fusion-positive cancers" to define those tumors that are identified as having either an
         <em>
          NTRK
         </em>
         fusion gene or a TRK fusion oncoprotein, depending on the diagnostic assay that is used. (See
         <a class="local">
          'Available diagnostic assays'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3181923033">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRK fusions are distinct from other oncogenic kinase fusions in their broad distribution across a variety of both adult and pediatric cancers  (
         <a class="graphic graphic_table graphicRef126089" href="/z/d/graphic/126089.html" rel="external">
          table 1
         </a>
         ). This distribution follows two general patterns:
        </p>
        <p class="headingAnchor" id="H2736495651">
         <span class="h3">
          Rare cancers enriched for TRK fusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRK fusions are enriched in several rare cancer types (occurring at estimated frequencies as high as &gt;90 percent in select series). These histologies include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital infantile fibrosarcoma [
         <a href="#rid10">
          10-14
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital mesoblastic nephroma (cellular subtype) [
         <a href="#rid11">
          11,15
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secretory breast carcinoma [
         <a href="#rid16">
          16,17
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mammary analogue secretory carcinoma (MASC) of the salivary gland [
         <a href="#rid18">
          18-20
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In general, these cancers present in children (including infants) and young adults, although secretory breast carcinoma and MASC of the salivary gland predominately occur in adolescence or later in life, respectively [
         <a href="#rid17">
          17,21,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3382.html" rel="external">
          "Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'Secretory (NTRK gene fusion positive)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/783.html" rel="external">
          "Pathology of breast cancer", section on 'Secretory carcinoma'
         </a>
         .)
        </p>
        <p>
         In some cases, the specific TRK fusion can help establish the diagnosis where routine pathology might be ambiguous. As an example, MASC of the salivary gland, which may be initially classified as "acinic cell carcinoma," can be diagnostically reclassified as MASC on the basis of identification of the recurrent translocation t(12;15)(p13;q25), which results in fusion of the ETS variant 6 (
         <em>
          ETV6
         </em>
         ) gene on chromosome 12 and the
         <em>
          NTRK3
         </em>
         gene on chromosome 15 to form the fusion gene
         <em>
          ETV6-NTRK3
         </em>
         . The identification of this fusion is pathognomonic for MASC, as it has not been demonstrated in any other salivary gland tumors [
         <a href="#rid18">
          18,23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1645166316">
         <span class="h3">
          Common cancers with low to intermediate frequency of TRK fusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRK fusions are also found in many common cancers  (
         <a class="graphic graphic_table graphicRef126089" href="/z/d/graphic/126089.html" rel="external">
          table 1
         </a>
         ), albeit at a much lower frequency (often &lt;1 percent [
         <a href="#rid25">
          25-28
         </a>
         ]):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-small cell lung cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast cancer other than secretory cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Colorectal and appendiceal cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pancreatic cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal cell cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head and neck cancer other than MASC
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoma, not otherwise specified
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melanoma [
         <a href="#rid29">
          29-31
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glioblastoma multiforme
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cholangiocarcinoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal stromal tumors
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3605594363">
         <span class="h3">
          Intermediate frequencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cancers may harbor TRK fusions at intermediate frequencies (1 percent or greater but less than 25 to 35 percent of cases) [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid cancer, particularly in children (frequency 2 to 28 percent, depending on the series [
         <a href="#rid25">
          25,33-36
         </a>
         ])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glioma (particularly select pediatric high-grade gliomas [
         <a href="#rid37">
          37
         </a>
         ])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific sarcomas, such as inflammatory myofibroblastic tumor [
         <a href="#rid38">
          38
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spitzoid neoplasms
        </p>
        <p>
        </p>
        <p>
         In addition, these fusions can very rarely be found in hematologic malignancies, such as acute lymphoblastic/myeloid leukemia, multiple myeloma, histiocytosis, and dendritic cell neoplasms [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1987430909">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The US Food and Drug Administration has approved a specific test that uses tissue next-generation sequencing for detection of NTRK fusion genes [
         <a href="#rid40">
          40
         </a>
         ]. There are a variety of other diagnostic modalities available for the identification of TRK fusions, each with different operating characteristics and tradeoffs. Here, we will review both the available diagnostic assays and the recommended testing algorithms that incorporate these methodologies.
        </p>
        <p class="headingAnchor" id="H2847505904">
         <span class="h3">
          Available diagnostic assays
         </span>
        </p>
        <p class="headingAnchor" id="H1488357576">
         <span class="h4">
          Tissue next-generation sequencing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the rarity of
         <em>
          NTRK
         </em>
         gene fusions in most cancers, assays that evaluate exclusively for the presence of
         <em>
          NTRK
         </em>
         gene fusions are impractical in most cases. Instead, next-generation sequencing (NGS, also called massively parallel sequencing) tests capable of evaluating for all classes of potentially actionable genomic alterations (single-nucleotide variants, indels, copy number alterations, structural rearrangements) across dozens or even hundreds of genes simultaneously are favored. This allows the assessment of
         <em>
          NTRK
         </em>
         gene fusions in conjunction with other tumor-agnostic biomarkers (ie, high levels of microsatellite instability/deficient mismatch repair) as well as any relevant tumor-specific biomarkers. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         .)
        </p>
        <p>
         NGS tests can be performed using DNA, RNA, or both. Although sequencing of either DNA or RNA can detect
         <em>
          NTRK
         </em>
         gene fusions, multiple technical considerations make RNA-based methods superior for this purpose. Specifically:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sensitivity of DNA-based NGS for
         <em>
          NTRK
         </em>
         gene fusion detection is lower, particularly for fusions involving
         <em>
          NTRK
         </em>
         2 or
         <em>
          NTRK3
         </em>
         other than those involving
         <em>
          ETV6
         </em>
         . (See
         <a class="local">
          'Basic biology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         These limitations of DNA-based NGS are the result of both large and repetitive introns of
         <em>
          NTRK2
         </em>
         and
         <em>
          NTRK3
         </em>
         , as well as the diversity of potential fusion partners. By comparison, some RNA-based sequencing methodologies are capable of detecting any fusion involving
         <em>
          NTRK1
         </em>
         ,
         <em>
          NTRK2
         </em>
         , or
         <em>
          NTRK3
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DNA-based sequencing may detect complex or ambiguous structural rearrangements of uncertain significance involving the
         <em>
          NTRK
         </em>
         genes. These typically manifest as structural rearrangements that do not appear to include the TRK kinase domain or in which the upstream partner cannot be resolved. By comparison, RNA-based sequencing preferentially detects rearrangements that result in expressed transcripts, thus resulting in improved specificity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3335326116">
         <span class="h4">
          Plasma next-generation sequencing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Currently available, plasma-based, cell-free DNA assays (sometimes referred to as "liquid tumor biopsies") are not optimal for the detection of
         <em>
          NTRK
         </em>
         gene fusions. Although the identification of an
         <em>
          NTRK
         </em>
         gene fusion using plasma NGS can help select patients for TRK inhibitor therapy, the absence of an
         <em>
          NTRK
         </em>
         gene fusion in plasma should not be interpreted as definitive evidence that an
         <em>
          NTRK
         </em>
         gene fusion is not present in a patient's cancer. In this situation, tumor-based testing is recommended. (See
         <a class="local">
          'Testing algorithms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H363326297">
         <span class="h4">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to its use in other cancers (eg, anaplastic lymphoma kinase [ALK] immunohistochemistry [IHC] in ALK fusion-positive lung cancers), IHC can be performed as a potential screening tool for TRK fusion oncogenes based on the fact that
         <em>
          NTRK
         </em>
         gene fusions can result in moderate to high levels of TRK oncoprotein expression, while many non-central nervous system (CNS) normal tissues do not express TRK receptors to a meaningful degree.
        </p>
        <p>
         A positive test in the right context thus serves as a surrogate for the presence of an
         <em>
          NTRK
         </em>
         gene fusion. A pan-TRK antibody (EPR17341, Ventana, Roche) is available as an in vitro diagnostic device for the detection of
         <em>
          NTRK
         </em>
         gene fusions [
         <a href="#rid41">
          41
         </a>
         ]. The epitope for this antibody is located in a conserved region of the C-terminus of TRKA, TRKB, and TRKC. Preliminary studies have demonstrated excellent sensitivity and specificity for this antibody in the detection of TRK fusion oncogenes [
         <a href="#rid42">
          42
         </a>
         ]. It is important, however, to consider that TRK expression is normal and expected in certain organs (specifically in the CNS). As such, IHC positivity can occasionally be seen in cancers without TRK fusions [
         <a href="#rid43">
          43
         </a>
         ] including, in our experience, tumors with neuroendocrine differentiation. For this reason, we recommend that, in tumors in which TRK fusions are rare, NGS be used in IHC-positive cases, when available, to confirm the positive result [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Testing algorithms'
         </a>
         below.)
        </p>
        <p>
         It is also important to recognize that overall expression intensity, as well as the specific staining localization, can be dictated by the upstream fusion partner. In our experience,
         <em>
          ETV6-NTRK3
         </em>
         fusions in particular appear to be often associated with relatively faint staining, and a false negative result on immunohistochemistry [
         <a href="#rid44">
          44
         </a>
         ]. Similarly, pan-TRK IHC is challenging to interpret in gastrointestinal stromal tumors, and we recommend against its use in this setting. Thus, both experienced pathologists and proper controls are required for proper interpretation of this assay.
        </p>
        <p class="headingAnchor" id="H1572462636">
         <span class="h4">
          Fluorescence in situ hybridization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluorescence in situ hybridization (FISH) break-apart assays can be used to detect the presence of an
         <em>
          NTRK
         </em>
         gene fusion. Three separate FISH tests need to be performed to detect fusions involving
         <em>
          NTRK1
         </em>
         ,
         <em>
          NTRK2
         </em>
         , and
         <em>
          NTRK3
         </em>
         . This increases the amount of tissue required to successfully perform all three assays. For this reason, the primary indication for FISH testing has been the evaluation of
         <em>
          NTRK
         </em>
         gene fusions in tumor types that harbor a specific pathognomonic fusion (for example, infantile fibrosarcoma, which nearly always harbors
         <em>
          ETV6-NTRK3
         </em>
         fusions). The interpretation of a positive FISH result is also subject to interobserver variability. Another limitation is that FISH break-apart tests generally cannot identify the upstream fusion partner. Finally, FISH break-apart assays may be falsely negative for fusions resulting from small intrachromosomal deletions/rearrangements, as is often the case with
         <em>
          NTRK1
         </em>
         fusions.
        </p>
        <p class="headingAnchor" id="H1723870246">
         <span class="h4">
          Reverse transcriptase polymerase chain reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reverse transcriptase polymerase chain reaction (RT-PCR) probes are designed to detect specific fusion events. For example, probes can be designed to detect
         <em>
          ETV6-NTRK3
         </em>
         , but these probes do not allow the detection of other fusions. This makes the use of this test relatively limited.
        </p>
        <p class="headingAnchor" id="H4239183977">
         <span class="h3">
          Testing algorithms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complexity of diagnostic assays and the variable frequency of these events across cancer types have led to the development of various testing algorithms to detect TRK fusions [
         <a href="#rid22">
          22,25,45,46
         </a>
         ]. We recommend the following approach, which is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef126093" href="/z/d/graphic/126093.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H3107918020">
         <span class="h4">
          Tumors with a high frequency of TRK fusions (&gt;20 percent)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For tumor types with a high frequency of TRK fusions, we recommend dedicated screening for TRK fusions, typically using pan-TRK IHC. FISH is a reasonable alternative to pan-TRK IHC.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive result
         </strong>
         – In these high-TRK-prevalence tumor types, pan-TRK IHC alone may be considered sufficient evidence of a TRK fusion oncoprotein, and confirmatory orthogonal testing could be deferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative result
         </strong>
         – Given the high prevalence of TRK fusions in these tumor types and the possibility of false negatives with pan-TRK IHC or FISH, we recommend proceeding to secondary screening, ideally using RNA-based NGS.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3007773477">
         <span class="h4">
          Tumors with a low or intermediate frequency of TRK fusions (&lt;20 percent)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this setting, we recommend broad screening with NGS, preferably using a methodology that incorporates both DNA and RNA sequencing (if available):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive result
         </strong>
         – A positive result is considered to be any positive test using RNA-based methods, or a DNA-based test that resolves an upstream partner and is predicted to be in frame and to contain the full-length TRK kinase domain. These results are sufficient, and no additional testing is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ambiguous result
         </strong>
         – Structural variants detected using DNA-based testing that do not meet the criteria specified above should be reflected to either pan-TRK IHC or RNA-based sequencing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative result
         </strong>
         – If the assay included RNA sequencing, we recommend no additional testing. If the assay included only DNA sequencing, we recommend the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For tumors in which DNA sequencing identified a tissue-relevant driver alteration (eg, epidermal growth factor receptor [
         <em>
          EGFR
         </em>
         ],
         <em>
          ALK
         </em>
         , c-ROS oncogene 1 [
         <em>
          ROS1
         </em>
         ],
         <em>
          KRAS
         </em>
         ,
         <em>
          NRAS
         </em>
         , or
         <em>
          BRAF
         </em>
         ), we do not recommend additional testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For tumor types known to harbor TRK fusions (eg, non-small cell lung cancer, thyroid cancer, pancreatic cancer, cholangiocarcinoma, sarcoma) with no concurrent driver alteration, we recommend reflexing to RNA-based screening (when available). In one proof-of-concept study, RNA sequencing in "driver-negative" non-small cell lung cancers identified occult kinase fusions in 11 percent of cases, including several TRKB and TRKC fusions [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In summary, there is no "one size fits all" approach to the detection of
         <em>
          NTRK
         </em>
         gene fusions and TRK fusion oncogenes. Testing algorithms are based on the pretest probability of TRK fusion positivity and the assays available to the pathologist or ordering clinician. With the approval of TRK inhibitors, we expect that testing providers will continue to iterate their assays to improve TRK fusion detection. Optimal detection using NGS-based assays requires inclusion of RNA sequencing. Current blood-based testing should be considered reliable when positive but generally insufficient for screening purposes, even for tests that explicitly include TRK detection in their assay design.
        </p>
        <p>
         Our approach is consistent with an ASCO provisional clinical opinion on somatic genomic testing in patients with advanced cancer, which stated that
         <em>
          NTRK
         </em>
         fusion testing should be performed in patients with metastatic or advanced solid tumors who may be candidates for TRK-inhibitor therapy, considering the prevalence of
         <em>
          NTRK
         </em>
         fusions in individual tumor types [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2726475029">
         <span class="h1">
          TREATMENT WITH TRK INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with TRK fusion-positive cancers should be offered treatment with a TRK inhibitor. For patients of all ages, we favor the use of
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         over
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , where available. Although comparative studies are not available, entrectinib carries a number of unique safety warnings and precautions not found with larotrectinib, including heart failure, skeletal fracture, hyperuricemia, and QT interval prolongation.
        </p>
        <p>
         The accurate and timely identification of TRK fusions is of immediate therapeutic importance given that TRK inhibitors have been shown to have robust and durable activity in TRK fusion-positive solid tumors. Specifically, two agents have been approved for the treatment of TRK fusion-positive cancers in the United States and elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          Larotrectinib
         </a>
         , a selective inhibitor of TRKA/B/C
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          Entrectinib
         </a>
         , a multikinase inhibitor of TRKA/B/C, c-ROS oncogene 1 (ROS1), and anaplastic lymphoma kinase (ALK)
        </p>
        <p>
        </p>
        <p>
         In the United States,
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         are both approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (
         <em>
          NTRK
         </em>
         ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. An oral solution formulation of larotrectinib is available to support administration for young children as well as adults unable to swallow capsules. Information on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fin-vitro-diagnostics%2Flist-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools&amp;token=4Q14HObFAvtwks2NX6iKvaedQj6h4iXSP%2BozMc2QFy1RqG6qFCDANuHegHhTBep5Fbne68BMm0wgtrWoFv6NK1PWcbFxfj3xfRlQL4zwcIumBqqAlUYq3f3JLtg9omY48Cdo9rizBppPdzi8L8p6lA%3D%3D&amp;TOPIC_ID=122713" target="_blank">
          US Food and Drug Administration-approved tests
         </a>
         to identify appropriate candidates is available.
        </p>
        <p>
         The European Medicines Agency has approved
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         for treatment of advanced TRK fusion-positive solid tumors. In Japan,
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         has been approved for treatment of 10 tumor types with an
         <em>
          NTRK
         </em>
         gene fusion (cholangiocarcinoma, neuroendocrine tumors, gynecologic malignancies, non-small cell lung, breast, thyroid, colorectal, and pancreatic cancer, salivary gland tumors, and soft tissue sarcoma). Neither drug is yet approved in the United Kingdom [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1018514671">
         <span class="h2">
          Efficacy of first-generation TRK inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approvals of both
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         in the United States, Europe, and elsewhere were based on integrated analyses of consecutively enrolled patients with TRK fusion-positive cancers across multiple clinical trials. The patient populations and efficacy data from two pooled analyses of patients treated with larotrectinib or entrectinib are shown in the table  (
         <a class="graphic graphic_table graphicRef126090" href="/z/d/graphic/126090.html" rel="external">
          table 2
         </a>
         ). These data can be summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Demographics
         </strong>
         – Both programs enrolled approximately 50 patients. All patients enrolled in the
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         program were adults, whereas 20 percent of those enrolled in the
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         program were children. A higher proportion of patients enrolled in the entrectinib program had known brain metastases at entry compared with the larotrectinib program (22 versus 2 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment outcomes
         </strong>
         – Key treatment outcomes for each drug are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Larotrectinib
         </strong>
         – In an early combined analysis of three phase I to II studies, 55 patients with various malignancies treated previously with chemotherapy received
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ]. The overall objective response rate across all tumor types was 76 percent (95% CI 61-85), including a 22 percent complete response rate. Responses were observed regardless of age, tumor type, or fusion type. Treatment was well tolerated, with no discontinuation of therapy due to adverse events. The most common grade ≥3 adverse events included increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST), fatigue, vomiting, dizziness, nausea, diarrhea, constipation, and cough. (See
         <a class="local">
          'Side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         An updated report of antitumor efficacy in an expanded cohort of 159 adults and children with TRK fusion-positive cancers (including the original 55 patients described above) treated with
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         confirmed these results and more fully characterized the durability of disease control [
         <a href="#rid50">
          50
         </a>
         ]. In this analysis with nearly three times the original number of patients, a similar objective response rate of 79 percent (95% CI 72-85) and a 16 percent complete response rate were achieved across tumor types. The median duration of response was 35.2 months, and the median progression-free survival was 28.3 months. No new safety signals were identified with longer treatment durations; the most common grade 3 or 4 toxicities were increased alanine aminotransferase (n = 8, 4 percent), and neutropenia (n = 5, 3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Entrectinib
         </strong>
         – In a pooled analysis of 54 adult patients with advanced/metastatic TRK fusion-positive solid tumors (10 tumor types, &gt;19 histopathologies) who were treated with
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, the overall objective response rate was 57 percent across all tumor types (95% CI 43-71), including a 7 percent complete response rate [
         <a href="#rid51">
          51
         </a>
         ]. Responses were observed across tumor types and fusion types. The median duration of response was 10.4 months and the median progression-free survival was 11 months. In a later analysis of this combined experience, with an expanded cohort of 121 adults with 14 tumor types and over 30 different histologies, the overall objective response rate was 61 percent (16 percent complete) with a median duration of response of 20 months (95% CI 13.0-38.2) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3822675794">
         <span class="h2">
          Timing of therapy for patients with advanced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         are approved for the treatment of advanced TRK fusion-positive cancers that "have no satisfactory alternative treatments or that have progressed following treatment." However, given the very high response rates and durable disease control achieved with TRK inhibitors, we recommend that TRK inhibitors be considered for first-line therapy in patients with advanced, fusion-positive advanced cancers. This follows paradigms established in other driver-positive cancers (eg, epidermal growth factor receptor [
         <em>
          EGFR
         </em>
         ]-mutant,
         <em>
          ALK
         </em>
         /
         <em>
          ROS1
         </em>
         fusion-positive non-small cell lung cancers) in which first-line targeted therapy has proven to be more efficacious than existing alternatives [
         <a href="#rid53">
          53,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">
          "Overview of the initial treatment of advanced non-small cell lung cancer", section on 'Driver mutation present'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H414453083">
         <span class="h2">
          Benefit of upfront or neoadjuvant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to advanced/metastatic disease, both
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         have also been approved for the treatment of locally advanced disease "where surgical resection is likely to result in severe morbidity." The most significant experience with neoadjuvant use of a TRK inhibitor has been in the preoperative use of larotrectinib for pediatric sarcomas [
         <a href="#rid55">
          55,56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among five pediatric patients with locally advanced sarcomas, all underwent successful curative-intent surgical resection, with three achieving complete or near-complete (&gt;98 percent treatment effect) pathologic responses with upfront
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         . These three patients remained off larotrectinib between 7 and 15 months postoperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All four patients with initially inoperable limb sarcomas were able to undergo limb-sparing surgery.
        </p>
        <p>
        </p>
        <p>
         While small case series such as this demonstrate the potential promise of neoadjuvant therapy with a TRK inhibitor, the main obstacle to broader use of this approach has been the timely preoperative identification of the presence of an
         <em>
          NTRK
         </em>
         gene or a TRK oncogene fusion. This has been easier to achieve in tumor types with high rates of TRK fusions, such as infantile fibrosarcoma. Anecdotally, we have administered
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         preoperatively to patients with locally advanced pancreatic cancer and esophageal cancer (one each) and achieved marked downstaging in both cases, permitting subsequent definitive therapy for both. Others have reported the use of upfront larotrectinib in a patient with stage II TRK fusion-positive pediatric thyroid cancer to allow more effective delivery of radioactive iodine [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3127266880">
         <span class="h2">
          Use in patients with central nervous system tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRK inhibitors have antitumor activity in patients with TRK fusion-positive central nervous system (CNS) metastases as well as primary CNS tumors.
        </p>
        <p>
         A subset of TRK fusion-positive cancers are histologic types with significant rates of brain metastasis, most commonly non-small cell lung cancer and melanoma. Thus, the activity of TRK inhibitors in the CNS is relevant for a subset of patients with TRK fusion-positive cancers. In addition, a subset of pediatric and adult primary brain tumors may also harbor TRK fusions and may benefit from a TRK inhibitor.
        </p>
        <p>
         The following summarizes what is known about the activity of the available TRK inhibitors in both primary and metastatic brain tumors:
        </p>
        <p class="headingAnchor" id="H3672200847">
         <span class="h3">
          Larotrectinib
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain metastasis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Various cancers
         </strong>
         – In the expanded 159-patient dataset that led to the approval of
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         , 13 patients (8 percent) were known to harbor CNS metastasis at baseline [
         <a href="#rid50">
          50
         </a>
         ]. In this dataset [
         <a href="#rid58">
          58,59
         </a>
         ], nine of 12 (75 percent) evaluable patients had overall responses (extracranial and intracranial) with larotrectinib. Of these patients, three had RECIST version 1.1 measurable intracranial disease: one had a complete intracranial response, one had a partial intracranial response, and one had stable intracranial disease, with the remaining patients achieving stable disease according to investigator assessment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lung cancers
         </strong>
         – Additional information is available from a report of 20 patients with TRK fusion-positive lung cancers; of the eight with evaluable CNS metastases, five (63 percent) had a partial response, with response duration ranging from 0.03 to 20.2 months [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary CNS tumors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The expanded 159-patient dataset that led to the approval of
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         included 18 patients with primary brain tumors; 14 had RECIST version 1.1 evaluable disease, and five of these (36 percent) had objective responses, including two complete responses [
         <a href="#rid58">
          58,59
         </a>
         ]. No patient had progressive disease as their best response. Median progression-free survival was 11 months. An exploratory subset analysis suggested that outcomes may be more favorable in pediatric brain tumor patients compared with their adult counterparts.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a later combined analysis of a larger group of 33 patients with TRK fusion-positive primary CNS tumors previously treated with standard chemotherapy and enrolled in the two clinical trials (including 19 high-grade gliomas, 8 low-grade gliomas),
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         was associated with a 30 percent objective response rate, the median time to response was 1.9 months, and the duration of treatment ranged from 1.2 to 31.3+ months [
         <a href="#rid61">
          61
         </a>
         ]. Although treatment-related adverse events developed in 24 percent of treated patients overall, they were severe (grade ≥3) in only 3 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1712223494">
         <span class="h3">
          Entrectinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          Entrectinib
         </a>
         is also active in patients with primary CNS tumors and CNS metastases [
         <a href="#rid51">
          51,62
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the 54-patient dataset that led to the approval of
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , 11 patients (22 percent) had CNS metastasis at baseline [
         <a href="#rid51">
          51
         </a>
         ]. Of these, intracranial responses were observed in six (55 percent) by blinded central review. In a later expanded cohort of this experience that included 26 patients with CNS metastases at baseline, there were 21 objective responses by blinded central review (58 percent), which included two complete responses [
         <a href="#rid52">
          52
         </a>
         ]. Median duration of response was 17.2 months (95% CI 6-29.4).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The phase II portion of the STARTRK-NG trial of
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         in children and young adults with solid extracranial or primary CNS tumors included 26 individuals with a target fusion in
         <em>
          NTRK
         </em>
         ,
         <em>
          ROS1
         </em>
         , or
         <em>
          ALK
         </em>
         ; 16 had primary CNS tumors [
         <a href="#rid62">
          62
         </a>
         ]. There were eight objective responses (50 percent), four complete.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3969610275">
         <span class="h2">
          Dosing
         </span>
        </p>
        <p class="headingAnchor" id="H2732340171">
         <span class="h3">
          Larotrectinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adults and children with a body surface area (BSA) of at least 1.0 m
         <sup>
          2
         </sup>
         , the recommended dose of
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         is 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For smaller children, the recommended dose is 100 mg/m
         <sup>
          2
         </sup>
         orally twice daily, and a liquid formulation is available.
        </p>
        <p class="headingAnchor" id="H1336738823">
         <span class="h3">
          Entrectinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recommended dose of
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         in adults is 600 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. For children aged ≥12 years, dosing is based on BSA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BSA &gt;1.5 m
         <sup>
          2
         </sup>
         : 600 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BSA 1.11 to 1.5 m
         <sup>
          2
         </sup>
         : 500 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BSA 0.91 to 1.10 m
         <sup>
          2
         </sup>
         : 400 mg once daily
        </p>
        <p>
        </p>
        <p>
         The drug is not approved for children under the age of 12 years, and a liquid formulation is not available.
        </p>
        <p class="headingAnchor" id="H1761013959">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         A summary of the overall safety profile in expanded cohorts of patients, as reported in the United States prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D9525f887-a055-4e33-8e92-898d42828cd1&amp;token=Tc3hLXXS9Zun6xHQiU9EQKtFXv3RHmwlKMSNwcc%2BLIUUqCVMaIDtHVxpXge1ujl5JUaAarLEna8AEioAXHcqalX0BrErSJ3yterxvE9ConaBRoClxTkceJhZfiAumAhz&amp;TOPIC_ID=122713" target="_blank">
          larotrectinib
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc7c71b0c-2549-4495-86b6-c2807fa54908&amp;token=upYV5UGI8L5npy99TSv2fWHz2yGFfz4CA02uXt7Me5jR0PeFhf%2F%2BXpqaZq3cQXbWSDXT5ttK%2Fnvch5wSrorMIpEInzSnFYI6q792VOwr408v9IkRLRiUW16avzRGcvOI&amp;TOPIC_ID=122713" target="_blank">
          entrectinib
         </a>
         , is shown in the table  (
         <a class="graphic graphic_table graphicRef126091" href="/z/d/graphic/126091.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3191392963">
         <span class="h3">
          On-target adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The TRK pathway controls appetite, balance, and pain sensitivity and TRK inhibitors can cause adverse effects related to these on-target effects [
         <a href="#rid63">
          63
         </a>
         ]. As a group, these adverse effects have been underrecognized and underreported. Data on the clinical presentation, frequency, and natural history of weight gain, dizziness, and withdrawal pain are available from a single-institution series of 96 patients who received at least one dose of a tyrosine kinase inhibitor (TKI) with potent anti-TRK activity [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weight gain
         </strong>
         – In this same series, weight gain was reported in 53 percent (51 of 96 patients); median time to onset was one month, and the frequency and severity of weight gain increased with longer time on therapy [
         <a href="#rid63">
          63
         </a>
         ]. Weight gain was not due to worsening fluid retention, but to increased adipose tissue, as assessed radiographically. Eight of the ten patients who received pharmacologic management (glucagon-like peptide 1 analogs,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         , sibutramine, or
         <a class="drug drug_general" data-topicid="9765" href="/z/d/drug information/9765.html" rel="external">
          phentermine
         </a>
         , either alone or in combination) lost weight or stopped gaining weight. The contribution of diet and exercise to weight control could not be assessed, although these were recommended by the investigators.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recommendations include serial monitoring of weight on TRK inhibitor therapy, paying careful attention to diet and increased exercise, pharmacologic management (potentially weigh the help of an endocrinologist or weight loss specialist), and ultimately TRK inhibitor dose reduction for moderate to severe and refractory weight gain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dizziness
         </strong>
         – Dizziness was observed in 41 percent (39 of 96) of the patients in this series; six had concurrent ataxia [
         <a href="#rid63">
          63
         </a>
         ]. The median time to onset was two weeks, (range 3 days to 16 months). Symptoms were described as positional light-headedness most often (33 percent), but also as imbalance (18 percent), vertigo (8 percent), or mixed (5 percent). Dizziness was accompanied by orthostatic hypotension in 21 percent (8 of 39 patients), although signs of volume depletion were absent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recommendations include carefully characterizing the type of dizziness that patients experience as supportive care measures can vary depending on the presentation. For example,
         <a class="drug drug_general" data-topicid="9597" href="/z/d/drug information/9597.html" rel="external">
          meclizine
         </a>
         seemed beneficial for individuals with vertigo, and
         <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">
          midodrine
         </a>
         was considered for patients with orthostasis. Ultimately, the most effective intervention was dose reduction in refractory cases, which led to symptom resolution in 7 of 9 patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Withdrawal pain
         </strong>
         – Given that TRK inhibitors can modulate pain receptors, chronic inhibition of TRK signaling may be associated with an increased setpoint for pain neurotransmitter signaling [
         <a href="#rid64">
          64
         </a>
         ]. Drug discontinuation can thus result in withdrawal pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Withdrawal pain was observed in 28 of 81 patients (34 percent) treated with at least one dose of a TKI with potent anti-TRK activity who discontinued treatment at some point [
         <a href="#rid63">
          63
         </a>
         ]. Symptoms were described as diffuse achiness, muscle pain, and/or allodynia often accompanied by headache. The median time to onset was two days, and severity was grade 1, 2, or 3 in 12, 11, and 11 percent, respectively. For patients who permanently discontinued therapy, the median duration of flare was 14 days (range 10 to 26 days). For those who temporarily discontinued therapy, the median duration was three days (range one to seven days), which was consistent with the median duration of drug hold (three days). Patients who had been taking the TRK inhibitor for longer than six months were more likely to experience withdrawal pain (63 versus 13 percent), and opioid administration prior to drug withdrawal was not beneficial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pharmacologic interventions including opioids and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         are of modest benefit in many patients. By contrast, for patients who temporarily discontinue therapy, restarting the TRK inhibitor results in rapid and often complete relief. For patients who have to discontinue therapy permanently, down-titration of TRK inhibitor therapy (25 percent decrease in dose every seven days) was beneficial in at least one patient.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2154943968">
         <span class="h3">
          Hepatotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both agents can cause elevation in liver enzymes, which may be severe. The United States prescribing information for both drugs recommends that liver tests, including AST and ALT, be monitored every two weeks during the first month of treatment, then monthly thereafter, as clinically indicated. Recommendations are provided for dose modifications for severe hepatotoxicity during therapy.
        </p>
        <p class="headingAnchor" id="H1625346462">
         <span class="h3">
          Neurotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic adverse events are common with both drugs (&gt;50 percent) but are severe (grade 3 or 4) in fewer than 10 percent. The majority develop within the first three months of treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Larotrectinib
         </strong>
         – Among the grade 3 or worse neurologic toxicities occurring with
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         are delirium, dysarthria, dizziness, gait disturbance, and paresthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Entrectinib
         </strong>
         – A broader spectrum of CNS effects has been seen with
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , which is not surprising since the drug was designed to cross the blood-brain barrier [
         <a href="#rid65">
          65
         </a>
         ]. These include cognitive impairment (27 percent all grade, including confusional state, disturbance in attention, memory impairment, aphasia, mental status changes, hallucinations, and delirium), mood disorders (10 percent all grade, including anxiety, depression, and agitation), dizziness (38 percent all grade), sleep disturbance (14 percent all grade), and vision disorders (21 percent all grade, including blurred vision, photophobia, diplopia, visual impairment, and vitreous floaters).
        </p>
        <p>
        </p>
        <p>
         Dose modification guidelines are available in the United States prescribing information for both drugs for patients who develop severe neurotoxicity during therapy.
        </p>
        <p class="headingAnchor" id="H2353516160">
         <span class="h3">
          Other toxicities specific to entrectinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the rate, number, and severity of adverse events all appear to be generally more favorable with
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         .
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          Entrectinib
         </a>
         carries a number of unique safety warnings and precautions not found with larotrectinib, including congestive heart failure, skeletal fracture, hyperuricemia, and QT interval prolongation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart failure
         </strong>
         – Across clinical trials, congestive heart failure has occurred in 3.4 percent of patients treated with
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , including grade 3 heart failure (2.4 percent). The median time to onset was two months. The United States prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc7c71b0c-2549-4495-86b6-c2807fa54908&amp;token=upYV5UGI8L5npy99TSv2fWHz2yGFfz4CA02uXt7Me5jR0PeFhf%2F%2BXpqaZq3cQXbWSDXT5ttK%2Fnvch5wSrorMIpEInzSnFYI6q792VOwr408v9IkRLRiUW16avzRGcvOI&amp;TOPIC_ID=122713" target="_blank">
          entrectinib
         </a>
         recommends assessment of left ventricular ejection fraction prior to initiation of entrectinib in patients with heart failure or known risk factors for congestive heart failure, and that patients be closely monitored for clinical signs and symptoms of congestive heart failure, including shortness of breath and edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          QT interval prolongation
         </strong>
         – Across clinical trials, 3 percent of patients treated with
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         who had at least one electrocardiogram (ECG) during treatment had prolongation of the corrected QT (QTc) interval, including some &gt;500 milliseconds. Monitor patients who have or who are at significant risk for QTc interval prolongation, including those with known long QT syndrome, clinically significant bradyarrhythmia, and severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. The United States prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc7c71b0c-2549-4495-86b6-c2807fa54908&amp;token=upYV5UGI8L5npy99TSv2fWHz2yGFfz4CA02uXt7Me5jR0PeFhf%2F%2BXpqaZq3cQXbWSDXT5ttK%2Fnvch5wSrorMIpEInzSnFYI6q792VOwr408v9IkRLRiUW16avzRGcvOI&amp;TOPIC_ID=122713" target="_blank">
          entrectinib
         </a>
         recommends assessment of the QT interval and electrolytes at baseline and periodically during treatment, particularly for those with known long QT syndrome, clinically significant bradyarrhythmia, and severe or uncontrolled heart failure or who are taking other medicinal products associated with QT prolongation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skeletal fractures
         </strong>
         –
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          Entrectinib
         </a>
         increases the risk of fractures (5 percent of adult patients and 25 percent of pediatric patients in combined clinical trial data reported in the United States prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc7c71b0c-2549-4495-86b6-c2807fa54908&amp;token=upYV5UGI8L5npy99TSv2fWHz2yGFfz4CA02uXt7Me5jR0PeFhf%2F%2BXpqaZq3cQXbWSDXT5ttK%2Fnvch5wSrorMIpEInzSnFYI6q792VOwr408v9IkRLRiUW16avzRGcvOI&amp;TOPIC_ID=122713" target="_blank">
          entrectinib
         </a>
         ). In children, these have occurred mainly in the setting of minimal or no trauma, although some patients have had radiologic abnormalities suggesting tumor involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperuricemia
         </strong>
         – Nearly 1 in 10 patients treated with
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         across clinical trials has experienced hyperuricemia, which was grade 4 in 1.7 percent and included one fatality due to tumor lysis syndrome. The United States prescribing information for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc7c71b0c-2549-4495-86b6-c2807fa54908&amp;token=upYV5UGI8L5npy99TSv2fWHz2yGFfz4CA02uXt7Me5jR0PeFhf%2F%2BXpqaZq3cQXbWSDXT5ttK%2Fnvch5wSrorMIpEInzSnFYI6q792VOwr408v9IkRLRiUW16avzRGcvOI&amp;TOPIC_ID=122713" target="_blank">
          entrectinib
         </a>
         recommends assessment of serum uric acid levels prior to initiating therapy and periodically during treatment, and that patients be monitored for signs and symptoms of hyperuricemia.
        </p>
        <p>
        </p>
        <p>
         Specific dose reduction guidelines are available for patients who develop these toxicities.
        </p>
        <p class="headingAnchor" id="H2629880435">
         <span class="h2">
          Resistance and options for second-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other targeted therapies, the onset of acquired resistance may limit the efficacy of TRK inhibitors. Resistance to these agents appears to be mediated either by mutation of the TRK kinase domain (called "on-target" resistance) or, alternatively, by activation of bypass or downstream pathways (called "off-target" resistance) [
         <a href="#rid66">
          66-68
         </a>
         ].
        </p>
        <p>
         Currently, there are no approved drugs for the management of acquired resistance that develops on
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         or
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         . Two next-generation TRK inhibitors are currently in development to address patients with on-target resistance: selitrectinib (BAY 2731954, LOXO-195) and
         <a class="drug drug_general" data-topicid="143455" href="/z/d/drug information/143455.html" rel="external">
          repotrectinib
         </a>
         (TPX-0005). Both agents have shown preliminary activity in this setting [
         <a href="#rid69">
          69-71
         </a>
         ], and clinical trials (including some with expanded access) are ongoing (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03215511%3Fterm%3DNCT03215511%26draw%3D1%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMO%2FIAlPDqAnxkMmK7OBtKHNpjGV%2BhoAYYRWPD7Fj19SdTIacmAZgBGn18Dgf8m%2FQA%3D&amp;TOPIC_ID=122713" target="_blank">
          NCT03215511
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03206931%3Fterm%3DNCT03206931%26draw%3D1%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNZT8dd2S8ww5gTiibLBG9oFOBh277GAoCILNZwar4%2FLqxETODTLuPruIN%2BDlRt%2BHc%3D&amp;TOPIC_ID=122713" target="_blank">
          NCT03206931
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03093116%3Fterm%3DNCT03093116%26draw%3D1%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPM1ZAm7%2FFJyv%2BHLfpcRfuO9bFT8v0ZLDl%2Fcr7LVRMYKRI1WMpcTCZ47UylmowRyqWw%3D&amp;TOPIC_ID=122713" target="_blank">
          NCT03093116
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04094610%3Fterm%3DNCT04094610%26draw%3D1%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPXW6qykLMoJe09k%2FCLN4yzkaMOLJSTTPfTGZPk76mUw%2FKtDMRONjMeg4CXFKHoMls%3D&amp;TOPIC_ID=122713" target="_blank">
          NCT04094610
         </a>
         ).
        </p>
        <p>
         We recommend that any patient with a TRK fusion-positive tumor progressing after an initial response to
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         or
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         have a repeat molecular profile by tumor biopsy and/or cell-free DNA testing and be considered for referral to a participating clinical trial site. When a clinical trial option is not available, standard-of-care therapies that are specific to the patient's cancer type should be considered.
        </p>
        <p class="headingAnchor" id="H4247130932">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular biology and prevalence of TRK fusions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Structural rearrangements involving one of the neurotrophic tyrosine receptor kinas
         <em>
          e (NTRK
         </em>
         ) genes result in a tropomyosin receptor kinase (TRK) fusion oncoprotein that leads to overexpression of the kinase domain or constitutive activity of the kinase function, both of which drive uninterrupted downstream signaling messages and oncogenic transformation and tumor growth. (See
         <a class="local">
          'Basic biology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         TRK fusion oncogenes are distinct from other oncogenic kinase fusions in their broad distribution across a variety of both adult and pediatric cancers  (
         <a class="graphic graphic_table graphicRef126089" href="/z/d/graphic/126089.html" rel="external">
          table 1
         </a>
         ). This distribution follows two general patterns: rare cancers that are enriched for TRK fusions (eg, congenital infantile fibrosarcoma, secretory breast cancer, mammary analogue secretory carcinoma [MASC] of the salivary gland) and common cancers that have low to intermediate frequencies of TRK fusions. (See
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The diagnostic evaluation for TRK fusions is challenging and depends on the frequency with which TRK fusions are found in a given tumor type  (
         <a class="graphic graphic_table graphicRef126089" href="/z/d/graphic/126089.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Our suggested approach to diagnostic testing is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef126093" href="/z/d/graphic/126093.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment with TRK inhibitors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The presence of a TRK fusion defines a new diagnostic category for solid tumors, independent of site of origin, that share sensitivity to TRK inhibitors. Two such agents (
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         ) are now approved in the United States and elsewhere for treatment of TRK fusion-positive refractory solid tumors, regardless of the site of disease origin. (See
         <a class="local">
          'Treatment with TRK inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All patients with TRK fusion-positive cancers should be offered treatment with a TRK inhibitor:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients of all ages, we suggest
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         over
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , where available (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although comparative studies are not available, entrectinib carries a number of unique safety warnings and precautions not found with larotrectinib, including heart failure, skeletal fracture, hyperuricemia, and QT interval prolongation. (See
         <a class="local">
          'Other toxicities specific to entrectinib'
         </a>
         above and
         <a class="local">
          'Side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Among patients with metastatic disease, TRK inhibitor therapy should be considered as soon as a TRK fusion is identified. (See
         <a class="local">
          'Timing of therapy for patients with advanced disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with locally advanced disease in whom immediate surgical resection would result in significant morbidity, preoperative use of TRK inhibition has been associated with downstaging and favorable outcomes in limited series. (See
         <a class="local">
          'Benefit of upfront or neoadjuvant therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         TRK inhibitors have antitumor activity in patients with central nervous system (CNS) metastases as well as primary CNS tumors. (See
         <a class="local">
          'Use in patients with central nervous system tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         On-target adverse events such as weight gain and dizziness during therapy, and withdrawal pain with therapy discontinuation should be monitored carefully. (See
         <a class="local">
          'On-target adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The onset of acquired resistance may limit the efficacy of TRK inhibitors. Any patient with a TRK fusion-positive tumor progressing after an initial response to a TRK inhibitor should have a repeat molecular profile by tumor biopsy and/or cell-free DNA testing and, if possible, should be referred to a participating clinical trial site for second-line therapy options. (See
         <a class="local">
          'Resistance and options for second-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2771190829">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David Hyman, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1:e000023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 2012; 846:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulciani S, Santos E, Lauver AV, et al. Oncogenes in solid human tumours. Nature 1982; 300:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin JB, Segal RA. Growth, survival and migration: the Trk to cancer. Cancer Treat Res 2003; 115:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004; 6:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun 2014; 5:4846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000; 24:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998; 153:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orbach D, Brennan B, De Paoli A, et al. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer 2016; 57:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chmielecki J, Bailey M, He J, et al. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res 2017; 77:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JL, Lockwood CM, Albert CM, et al. Infantile NTRK-associated Mesenchymal Tumors. Pediatr Dev Pathol 2018; 21:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 2018; 31:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz DP, Sharma CS, Connolly E, et al. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast 2012; 21:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skálová A, Vanecek T, Simpson RH, et al. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion. Am J Surg Pathol 2016; 40:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop JA, Yonescu R, Batista D, et al. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol 2013; 44:1982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo J, Seethala RR, Sirintrapun SJ. Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor. Head Neck Pathol 2014; 8:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert CM, Davis JL, Federman N, et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. J Clin Oncol 2019; 37:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urano M, Nagao T, Miyabe S, et al. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol 2015; 46:94.
          </a>
         </li>
         <li class="breakAll">
          Skalova A, Bell D, Bishop JA, et al. Secretory carcinoma. In: WHO Classification of Head and Neck Tumours, 4th ed, El-Naggar AK, Chan JKC, Grandis JR, et al (Eds), International Agency for Research on Cancer, Lyon 2017. p.177.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 2019; 72:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020; 33:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamura R, Boichard A, Kato S, et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018; 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen EY, Goldman DA, Hechtman JF, et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin Cancer Res 2020; 26:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lezcano C, Shoushtari AN, Ariyan C, et al. Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 2018; 42:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh I, Tee MK, Botton T, et al. NTRK3 kinase fusions in Spitz tumours. J Pathol 2016; 240:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014; 5:3116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nies M, Vassilopoulou-Sellin R, Bassett RL, et al. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. J Clin Endocrinol Metab 2021; 106:e1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stosic A, Fuligni F, Anderson ND, et al. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma. Cancer Res 2021; 81:5625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JC, Ashok A, Liu C, Kang H. Real-World Experience of NTRK Fusion-Positive Thyroid Cancer. JCO Precis Oncol 2022; 6:e2100442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricarte-Filho JC, Halada S, O'Neill A, et al. The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. Cancer Genet 2022; 262-263:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014; 46:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 2020; 31:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor J, Pavlick D, Yoshimi A, et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. J Clin Invest 2018; 128:3819.
          </a>
         </li>
         <li class="breakAll">
          FDA approves companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi. Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-companion-diagnostic-identify-ntrk-fusions-solid-tumors-vitrakvi (Accessed on July 25, 2022).
         </li>
         <li class="breakAll">
          Roche launches first IVD pan-TRK immunohistochemistry assay. Roche 2018. https://diagnostics.roche.com/global/en/news-listing/2018/TRK-immunohistochemistry-assay.html (Accessed on September 26, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol 2017; 41:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elfving H, Broström E, Moens LNJ, et al. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. Lung Cancer 2021; 151:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hondelink LM, Schrader AMR, Asri Aghmuni G, et al. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Eur J Cancer 2022; 173:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn 2019; 21:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 2019; 30:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benayed R, Offin M, Mullaney K, et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin Cancer Res 2019; 25:4712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper S, Bouvy JC, Baker L, et al. How should we assess the clinical and cost effectiveness of histology independent cancer drugs? BMJ 2020; 368:l6435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, De Braud F, Drilon A, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 2022; 28:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:2167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuBois SG, Laetsch TW, Federman N, et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer 2018; 124:4241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waguespack SG, Tewari SO, Busaidy NL, Zafereo ME. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease? JCO Precis Oncol 2022; 6:e2100467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon AE, DuBois SG, Farago AF, et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. J Clin Oncol 2018; 37:(suppl; abstr 2006).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen EY, Schram AM, Young RJ, et al. Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors. JCO Precis Oncol 2019; 3:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Tan DSW, Lassen UN, et al. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol 2022; 6:e2100418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 2022; 24:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol 2022; 24:1776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu D, Flory J, Lin A, et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol 2020; 31:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero JF, Laird JM, López-García JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 2000; 61:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer H, Ullah M, de la Cruz CC, et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol 2020; 22:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cocco E, Schram AM, Kulick A, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med 2019; 25:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016; 27:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo M, Misale S, Wei G, et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discov 2016; 6:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Nagasubramanian R, Blake JF, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov 2017; 7:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov 2018; 8:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyman D, Kummar S, Farago A, et al. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res 2019; 79:(suppl).
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 122713 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27843590" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520916" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Neurotrophins: roles in neuronal development and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367796" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The neurotrophin family of neurotrophic factors: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7144906" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oncogenes in solid human tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25527197" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : TRKing down an old oncogene in a new era of targeted therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12613191" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Growth, survival and migration: the Trk to cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15488758" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25204415" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The landscape of kinase fusions in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10895816" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9811336" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26849118" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069802" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28683589" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Infantile NTRK-associated Mesenchymal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29099503" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12450792" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22494666" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Secretory carcinoma of the breast: results from the survival, epidemiology and end results database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20410810" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26492182" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23773480" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23921806" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30592640" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456394" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456394" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31072837" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Testing algorithm for identification of patients with TRK fusion cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31375766" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30637364" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31871300" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29683819" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Primary and Metastatic Melanoma With NTRK Fusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27477320" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : NTRK3 kinase fusions in Spitz tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445538" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30333516" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : NTRK fusion-positive cancers and TRK inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33382403" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34535459" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35171659" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Real-World Experience of NTRK Fusion-Positive Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35092884" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24705251" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32891793" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29920189" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29920189" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29920189" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28719467" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33310622" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35933886" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31075511" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31268127" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31028088" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31896539" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32105622" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35144967" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27959700" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25470694" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30204247" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29606586" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35420905" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085007" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34850167" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35395680" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32422171" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Characterization of on-target adverse events caused by TRK inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10704997" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Wind-up of spinal cord neurones and pain sensation: much ado about something?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32383735" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31406350" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26884591" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26546295" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28578312" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30093503" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
